Lixivaptan (VPA-985) is a phase III pharmaceutical being developed by Cardiokine, Inc. a specialty pharmaceutical company based in Philadelphia, PA, focused on the development of pharmaceuticals for the treatment and prevention of cardiovascular diseases. Reference standards of Lixivaptan API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => Lixivaptan - API Standards [catalogue_number] => PA 65 30000 [category_ids] => ,78,75,70,76,82, [chemical_name] => [weight] => 473.93 [form] => C27H21ClFN3O2 [cas] => 168079-32-1 [pslug] => 168079-32-1-lixivaptan-api-pa6530000 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 65 30000
CAS :
Molecular Formula : C27H21ClFN3O2
Molecular Weight : 473.93
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
